There have so far only been three cancer vaccines approved by the FDA, and many others are now nearing the end of their clinical trials. Two of these were vaccines for HPV, which is responsible for 70% of cervical cancer. The most recent, and most exciting is the approval of Provenge last year, which is a vaccine for Prostate Cancer by Dendreon.

With a successful pathway through the commercialization and regulatory process now mapped out, companies are really starting to increase their work in this field to ensure success in clinical trials.

SMi's inaugural conference on Cancer Vaccines taking place on 19th & 20th September at the Copthorne Tara Hotel, London will provide attendees with a complete view of the cancer immunotherapy field, focusing on the discovery of new vaccines, developments in target identification and vaccine delivery strategies, this informative event will bring together key opinion leaders in the field to provide attendees with an in depth look into current advances in cancer vaccines.

Key benefits of attending

• Consider novel combination therapies in cancer vaccine development
• Understand effective process development strategies 
• Evaluate developments in cell based immunotherapeutics 
• Discover strategies to improve success and overcome current issues in clinical trials 
• Learn about clinical and regulatory design of immunotherapy programs 
• Hear from the industry on updates on the most recent successful candidates in Phase III 
• Develop monitoring immunotherapy outcomes 
• Network and learn from key opinion leaders from industry and academia
  

Quote Lab Bulletin and save £100.

For further information click here